NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
Read Moreby Lucy Parsons | Mar 19, 2021 | News | 0
Genomic HRD testing to be launched to support the introduction of this treatment regimen
Read Moreby Lucy Parsons | Jan 13, 2021 | News | 0
Updated analysis is from the Phase III IMbrave150 study
Read Moreby Selina McKee | Jul 14, 2020 | News | 0
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read Moreby Selina McKee | Jun 3, 2020 | News | 0
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read Moreby Anna Smith | Oct 28, 2019 | News | 0
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Read Moreby Selina McKee | Sep 24, 2019 | News | 0
Roche’s drug has been used for years to treat wet AMD, an indication for which it is not specifically licensed
Read Moreby Anna Smith | May 3, 2019 | News | 0
The recommendation is for the drug in combination with Avastin (bevacizumab), carboplatin and paclitaxel.
Read Moreby Anna Smith | Feb 20, 2019 | News | 0
Pfizer has announced European approval of its Avastin biosimilar Zirabev.
Read Moreby Anna Smith | Jan 2, 2019 | News | 0
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read Moreby Selina McKee | Sep 24, 2018 | News | 0
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Read Moreby Selina McKee | Sep 6, 2018 | News | 0
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Read Moreby Selina McKee | May 8, 2018 | News | 0
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
